

Riccardo Bientinesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7543227/publications.pdf>

Version: 2024-02-01

27
papers

421
citations

933264

10
h-index

752573

20
g-index

31
all docs

31
docs citations

31
times ranked

494
citing authors

#	ARTICLE	IF	CITATIONS
1	Male sling placement for post-prostatectomy incontinence can involve a lengthy learning curve: A multi-outcome assessment via cumulative sum failure analysis. <i>Urologia</i> , 2022, 89, 521-528.	0.3	1
2	A multi-surgeon learning curve analysis of overall and site-specific positive surgical margins after RARP and implications for training. <i>Journal of Robotic Surgery</i> , 2022, , 1.	1.0	5
3	The new surgical robotic platform HUGO TM RAS: System description and docking settings for robot-assisted radical prostatectomy. <i>Urologia</i> , 2022, 89, 603-609.	0.3	35
4	Methylation study of the Paris system for reporting urinary (TPS) categories. <i>Journal of Clinical Pathology</i> , 2021, 74, 102-105.	1.0	7
5	Bladder cancer in the time of machine learning: Intelligent tools for diagnosis and management. <i>Urologia</i> , 2021, 88, 94-102.	0.3	9
6	Lifestyle in urology: Benign diseases. <i>Urologia</i> , 2021, 88, 163-174.	0.3	1
7	Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments. <i>Neurourology and Urodynamics</i> , 2021, 40, 1500-1508.	0.8	8
8	Multiparametric magnetic resonance imaging of the prostate: Lights and shadows. <i>Urologia</i> , 2021, 88, 280-286.	0.3	5
9	Comments on a case of ureteropelvic junction obstruction with late progression in an adult female. <i>Urologia</i> , 2021, 88, 247-250.	0.3	0
10	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 269-277.	1.4	13
11	Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 637-644.	0.9	15
12	Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies. <i>International Neurourology Journal</i> , 2020, 24, 118-126.	0.5	8
13	Patient pad count is a poor measure of urinary incontinence compared with 48h pad test: results of a large-scale multicentre study. <i>BJU International</i> , 2019, 123, E69-E78.	1.3	18
14	Objectively improving appropriateness of absorbent products provision to patients with urinary incontinence: The DIAPPER study. <i>Neurourology and Urodynamics</i> , 2018, 37, 485-495.	0.8	6
15	Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1989-1997.	0.9	7
16	KV7 channels in the human detrusor: channel modulator effects and gene and protein expression. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 127-137.	1.4	17
17	Male sexual dysfunction in patients with chronic end-stage renal insufficiency and in renal transplant recipients. <i>Archivio Italiano Di Urologia Andrologia</i> , 2016, 87, 299.	0.4	34
18	The Occult Urothelial Cancer. <i>Urologia</i> , 2016, 83, 55-60.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review. <i>International Urogynecology Journal</i> , 2016, 27, 1633-1644.	0.7	3
20	Paraneoplastic Hyperinsulinism due to Renal Cell Carcinoma Treated With Robotic Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e107-e109.	0.9	2
21	Paraneoplastic Dermatomyositis Associated With Panurothelial Transitional Cell Carcinoma: A Case Report and Literature Review. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e199-e201.	0.9	5
22	Endourethral Migration of a Hem-o-Lok Clip after Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Urologia</i> , 2015, 82, 242-244.	0.3	9
23	Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?. <i>International Urogynecology Journal</i> , 2015, 26, 629-640.	0.7	15
24	Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 433-448.	2.5	49
25	OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder neck dysfunction: Objective and patient-reported outcomes. <i>Neurourology and Urodynamics</i> , 2014, 33, 142-146.	0.8	11
26	Mirabegron: a review of recent data and its prospects in the management of overactive bladder. <i>Therapeutic Advances in Urology</i> , 2012, 4, 315-324.	0.9	98
27	Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. <i>BJU International</i> , 2012, 110, E837-44.	1.3	31